Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week's blog reports on highlights from Day 1 of the IMF Patient & Family Seminar in Boca Raton, Florida, including immunotherapy combinations, long-term dexamethasone use, defining a cure for myeloma, advances in clinical trials, and more. READ THE BLOG.
The International Myeloma Foundation (IMF) and the International Myeloma Working Group (IMWG) are proud to announce the recipients of this year’s Robert A. Kyle Achievement Award and Brian G.M. Durie Outstanding Achievement Award, Dr. Hermann Einsele and Dr. Noopur Raje. READ THE PRESS RELEASE.
La reunión de este mes del Grupo de Apoyo Las Voces de Mieloma se llevará a cabo en línea el 16 de junio, de 10:00 a. m. a 11:00 a. m. (hora estándar del Pacífico). El tema será "Necesidades de los pacientes con mieloma múltiple en 2026: ¿ha cambiado algo tras la innovación?" La invitada será Teresa Regueiro, presidenta y fundadora de la Comunidad Española de Pacientes con Mieloma Múltiple (CEMMP), además de una reconocida defensora de los pacientes. REGÍSTRESE AQUÍ.
The next Las Voces de Mieloma (Spanish/virtual) support group will take place on June 16, from 10 a.m. - 11 a.m. PST. Its topic is "The Needs of Patients with Multiple Myeloma in 2026: Has Innovation Changed Anything?" The Guest Speaker will be Teresa Regueiro, the founder and president of the Spanish Multiple Myeloma Patient Community (CEMMP) and a well-known patient advocate. REGISTER HERE.
On Monday, June 8, Sanofi announced in a press release that “the European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma across all existing indications for Sarclisa intravenous (IV) formulation." LEARN MORE.
From August 18–24, 2026, intrepid cyclists — patients, care partners, and healthcare professionals — will cross Iceland’s breathtaking landscapes to raise vital funds for the International Myeloma Foundation’s mission.
